GAIN THERAPEUTICS INC (GANX)

US36269B1052 - Common Stock

3.85  +0.12 (+3.22%)

News Image
2 days ago - InvestorPlace

GANX Stock Earnings: Gain Therapeutics Beats EPS for Q4 2023

GANX stock results show that Gain Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

News Image
2 days ago - Gain Therapeutics, Inc.

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...

News Image
13 days ago - Gain Therapeutics, Inc.

Gain Therapeutics to Present at Public Ventures Discovery Day

Gain Therapeutics’ Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and Aberdeen Investment Management President Jeb Terry, Sr.

News Image
13 days ago - Gain Therapeutics, Inc.

Gain Therapeutics to Present at Public Ventures Discovery Day

Gain Therapeutics’ Former CEO and current Board Member Eric Richman to participate in fireside chat hosted by Public Ventures President Lou Basenese and...

News Image
23 days ago - Gain Therapeutics, Inc.

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction

News Image
23 days ago - Gain Therapeutics, Inc.

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease

Data support the ability of GT-02287 to prevent several steps in the disease cascade resulting from GCase misfolding and dysfunction...

News Image
a month ago - Gain Therapeutics, Inc.

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease

BETHESDA, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...

News Image
a month ago - Gain Therapeutics, Inc.

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST

News Image
a month ago - Gain Therapeutics, Inc.

Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight

Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST...

News Image
2 months ago - Gain Therapeutics, Inc.

UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm

News Image
2 months ago - Gain Therapeutics, Inc.

UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level...

News Image
2 months ago - Gain Therapeutics, Inc.

Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease

Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm

News Image
3 months ago - Gain Therapeutics, Inc.

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s disease

News Image
3 months ago - Gain Therapeutics, Inc.

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s disease...

News Image
3 months ago - Seeking Alpha

Gain Therapeutics files to sell 744,026 shares of common stock for holders (NASDAQ:GANX)

Gain Therapeutics has filed a prospectus for the resale of 744,026 shares of common stock, but it is not an offer to sell.

News Image
4 months ago - Gain Therapeutics, Inc.

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Compounds significantly restored β-Gal function and reduced intracellular toxic substrates in model of GM1 gangliosidosis Results published in PLOS ONE in...

News Image
4 months ago - Gain Therapeutics, Inc.

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

BETHESDA, Md., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery...

News Image
4 months ago - Gain Therapeutics, Inc.

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

BETHESDA, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the closing of an...

News Image
4 months ago - Seeking Alpha

Gain Therapeutics prices stock and warrants offering to raise $9.4M (NASDAQ:GANX)

Gain Therapeutics announces pricing of $9.4 million public offering and concurrent private placement, with proceeds to advance neurodegenerative disease...

News Image
4 months ago - Gain Therapeutics, Inc.

Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants

BETHESDA, Md., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an...

News Image
4 months ago - Seeking Alpha

Gain Therapeutics intends to offer its shares in a public offering (NASDAQ:GANX)

Gain Therapeutics plans to offer and sell shares and warrants in a public offering to fund development of its lead product candidate GT-02287.

News Image
4 months ago - Gain Therapeutics, Inc.

Gain Therapeutics Announces Proposed Public Offering

News Image
4 months ago - Gain Therapeutics, Inc.

Gain Therapeutics Announces Proposed Public Offering

BETHESDA, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that it is proposing to...

News Image
5 months ago - Gain Therapeutics, Inc.

Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule

News Image
5 months ago - Gain Therapeutics, Inc.

Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule...

News Image
6 months ago - InvestorPlace

These Apple Insiders Are Selling Shares of AAPL Stock

Apple stock is on the move Wednesday after several insiders at the company, including CEO Tim Cook, sold shares of AAPL.

News Image
6 months ago - InvestorPlace

Why Is Nvni Group (NVNI) Stock Down 8% Today?

Nvni Group is seeing shares of NVNI stock fall on Wednesday following the company's debut debut yesterday following a SPAC merger.